Crinetics Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Amortized Cost
Crinetics Pharmaceuticals, Inc. (CRNX) had Debt Securities, Available-for-sale, Amortized Cost of $1.14 billion as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-08-07
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $1.14B.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $1.18B.
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $1.09B.
- 2024-09-30: Debt Securities, Available-for-sale, Amortized Cost $543.36M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2025-06-30 | $1.14B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.18B 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $1.09B 10-Q · filed 2025-08-07 | |
| 2024-09-30 | $543.36M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $560.98M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $504.89M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $502.68M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $412.72M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $226.68M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $257.44M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $305.68M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $342.46M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $349.83M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $176.37M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $133.39M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $31.80M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $24.98M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $133.39M 10-Q · filed 2022-08-12 | $45.07M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $77.77M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $68.96M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $44.22M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $61.73M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $77.92M 10-K · filed 2021-03-30 | |
| 2019-09-30 | $64.90M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $85.02M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $94.23M 10-Q · filed 2019-05-13 | |
| 2018-12-31 | $118.84M 10-K · filed 2020-03-09 |